Advertisement
Mayo Clinic Proceedings Home

Treatment Discontinuations With New Oral Agents for Long-term Anticoagulation: Insights From a Meta-analysis of 18 Randomized Trials Including 101,801 Patients

      Abstract

      Objective

      To systematically examine discontinuation rates with new US Food and Drug Administration–approved oral anticoagulants (NOACs) in patients with various indications for long-term anticoagulation.

      Patients and Methods

      Poor adherence to medications is considered a potential and frequent cause of treatment failure. We searched the PubMed, Cochrane Central Register of Controlled Trials, EMBASE, EBSCO, Web of Science, and CINAHL databases for articles published from January 1, 2001, through September 15, 2013. The following Medical Subject Heading terms and/or keywords were used for our database searches: rivaroxaban, dabigatran, apixaban, new oral anticoagulants, oral thrombin inhibitors, and oral factor Xa inhibitors. Articles in English that focused on randomized controlled trials (RCTs) comparing NOACs (apixaban, dabigatran, and rivaroxaban) with conventional therapy or placebo were abstracted. Independent extraction of relevant data was performed by 2 authors. The primary end point of interest was discontinuation due to all causes. Other end points of interest were discontinuation due to adverse events, consent withdrawal, and nonadherence.

      Results

      Eighteen RCTs including a total of 101,801 patients were included for analysis. Total study drug discontinuation rates were not statistically different with NOACs in comparison to pharmacologically active comparators for treatment of venous thromboembolism/pulmonary embolism (risk ratio [RR], 0.91; 95% CI, 0.74-1.13; P=.40) and for NOACs in comparison to warfarin and aspirin for prevention of stroke in patients with atrial fibrillation (RR, 1.01; 95% CI, 0.87-1.17; P=.92). In contrast, in acute coronary syndromes, total study drug discontinuation with NOACs was significantly higher than with placebo (RR, 1.40; 95% CI, 1.07-1.83; P=.01). Overall discontinuations were comparable to those with active comparators.

      Conclusion

      Study drug discontinuations with NOACs were not significantly different from those with conventional drugs in treatment of venous thromboembolism/pulmonary embolism and prevention of stroke in patients with atrial fibrillation but were worse in acute coronary syndromes as noted in evidence from contemporary RCTs.

      Abbreviations and Acronyms:

      ACS (acute coronary syndrome), AF (atrial fibrillation), NOAC (new oral anticoagulant), PE (pulmonary embolism), RCT (randomized controlled trial), RR (risk ratio), VKA (vitamin K antagonist), VTE (venous thromboembolism)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Simpson S.H.
        • Eurich D.T.
        • Majumdar S.R.
        • et al.
        A meta-analysis of the association between adherence to drug therapy and mortality.
        BMJ. 2006; 333: 15
        • Osterberg L.
        • Blaschke T.
        Adherence to medication.
        N Engl J Med. 2005; 353: 487-497
        • Lavitola Pde L.
        • Sampaio R.O.
        • Oliveira W.A.
        • et al.
        Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation.
        Arq Bras Cardiol. 2010; 95: 749-755
        • Adam S.S.
        • McDuffie J.R.
        • Ortel T.L.
        • Williams Jr., J.W.
        Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
        Ann Intern Med. 2012; 157: 796-807
        • Komócsi A.
        • Vorobcsuk A.
        • Kehl D.
        • Aradi D.
        Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials.
        Arch Intern Med. 2012; 172: 1537-1545
        • De Caterina R.
        • Husted S.
        • Wallentin L.
        • et al.
        • Coordinating Committee
        New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
        J Am Coll Cardiol. 2012; 59: 1413-1425
        • Rodriguez R.A.
        • Carrier M.
        • Wells P.S.
        Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?.
        J Thromb Haemost. 2013; 11: 390-394
        • Bellamy L.
        • Rosencher N.
        • Eriksson B.
        Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate.
        Patient Prefer Adherence. 2009; 3: 173-177
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        • ROCKET AF Investigators
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.
        • et al.
        • ARISTOTLE Committees and Investigators
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Mega J.L.
        • Braunwald E.
        • Wiviott S.D.
        • et al.
        • ATLAS ACS 2–TIMI 51 Investigators
        Rivaroxaban in patients with a recent acute coronary syndrome.
        N Engl J Med. 2012; 366: 9-19
        • Schulman S.
        • Crowther M.A.
        How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.
        Blood. 2012; 119: 3016-3023
        • Kazmi R.S.
        • Lwaleed B.A.
        New anticoagulants: how to deal with treatment failure and bleeding complications.
        Br J Clin Pharmacol. 2011; 72: 593-603
        • Eikelboom J.W.
        • Wallentin L.
        • Connolly S.J.
        • et al.
        Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.
        Circulation. 2011; 123: 2363-2372
        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
        Ann Intern Med. 2009; 151: W65-W94
      1. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. http://www.cochrane-handbook.org. Updated March 2011. Accessed July 1, 2013.

        • Goldhaber S.Z.
        • Leizorovicz A.
        • Kakkar A.K.
        • et al.
        • ADOPT Trial Investigators
        Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
        N Engl J Med. 2011; 365: 2167-2177
        • Connolly S.J.
        • Eikelboom J.
        • Joyner C.
        • et al.
        • AVERROES Steering Committee and Investigators
        Apixaban in patients with atrial fibrillation.
        N Engl J Med. 2011; 364: 806-817
        • Bauersachs R.
        • Berkowitz S.D.
        • Brenner B.
        • et al.
        • EINSTEIN Investigators
        Oral rivaroxaban for symptomatic venous thromboembolism.
        N Engl J Med. 2010; 363: 2499-2510
        • Büller H.R.
        • Prins M.H.
        • Lensin A.W.
        • et al.
        • EINSTEIN–PE Investigators
        Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
        N Engl J Med. 2012; 366: 1287-1297
        • Agnelli G.
        • Gallus A.
        • Goldhaber S.Z.
        • et al.
        • ODIXa-DVT Study Investigators
        Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
        Circulation. 2007; 116: 180-187
        • Buller H.R.
        • Lensing A.W.
        • Prins M.H.
        • et al.
        • Einstein-DVT Dose-Ranging Study Investigators
        A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
        Blood. 2008; 112: 2242-2247
        • Schulman S.
        • Kearon C.
        • Kakkar A.K.
        • et al.
        • RE-COVER Study Group
        Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
        N Engl J Med. 2009; 361: 2342-2352
        • Agnelli G.
        • Buller H.R.
        • Cohen A.
        • et al.
        • AMPLIFY-EXT Investigators
        Apixaban for extended treatment of venous thromboembolism.
        N Engl J Med. 2013; 368: 699-708
        • Hori M.
        • Matsumoto M.
        • Tanahashi N.
        • et al.
        • J-ROCKET AF Study Investigators
        Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: the J-ROCKET AF study.
        Circ J. 2012; 76: 2104-2111
        • Ogawa S.
        • Shinohara Y.
        • Kanmuri K.
        Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation: the ARISTOTLE-J study.
        Circ J. 2011; 75: 1852-1859
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361 ([published correction appears in N Engl J Med. 2010;363(19):1877]): 1139-1151
        • Ezekowitz M.D.
        • Reilly P.A.
        • Nehmiz G.
        • et al.
        Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
        Am J Cardiol. 2007; 100: 1419-1426
        • Mega J.L.
        • Braunwald E.
        • Mohanavelu S.
        • et al.
        • ATLAS ACS-TIMI 46 Study Group
        Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
        Lancet. 2009; 374: 29-38
        • Alexander J.H.
        • Becker R.C.
        • Bhatt D.L.
        • et al.
        • APPRAISE Steering Committee and Investigators
        Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
        Circulation. 2009; 119: 2877-2885
        • Alexander J.H.
        • Lopes R.D.
        • James S.
        • et al.
        • APPRAISE-2 Investigators
        Apixaban with antiplatelet therapy after acute coronary syndrome.
        N Engl J Med. 2011; 365: 699-708
        • Oldgren J.
        • Budaj A.
        • Granger C.B.
        • et al.
        • RE-DEEM Investigators
        Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
        Eur Heart J. 2011; 32: 2781-2789
        • Rowley C.P.
        • Bernard M.L.
        • Brabham W.W.
        • et al.
        Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices.
        Am J Cardiol. 2013; 111: 1165-1168
        • Sørensen R.
        • Gislason G.
        • Torp-Pedersen C.
        • et al.
        Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study.
        BMJ Open. 2013; 3
        • Southworth M.R.
        • Reichman M.E.
        • Unger E.F.
        Dabigatran and postmarketing reports of bleeding.
        N Engl J Med. 2013; 368: 1272-1274
        • Testa S.
        • Paoletti O.
        • Zimmermann A.
        • Bassi L.
        • Zambelli S.
        • Cancellieri E.
        The role of anticoagulation clinics in the era of new oral anticoagulants.
        Thrombosis. 2012; 2012: 835356
        • Salanti G.
        • Higgins J.P.
        • Ades A.E.
        • Ioannidis J.P.
        Evaluation of networks of randomized trials.
        Stat Methods Med Res. 2008; 17: 279-301
        • Song F.
        • Loke Y.K.
        • Walsh T.
        • Glenny A.M.
        • Eastwood A.J.
        • Altman D.G.
        Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews.
        BMJ. 2009; 338: b1147